Replies to post #387893 on Anavex Life Sciences Corp (AVXL)

[Anshu2]

Doc: How does the new deck answer any Qs? I have the following:

1. What is the n used for ADAS-cog (and CDR-SB) p-value calculation?
2. Why the baseline numbers on slide 16 and 21 do not match?

Note that if slide #21 the mean-change is not the same as subtraction of means --- then baseline mean score must include 'all" the patients and the treatment mean score includes only the patients with 48-week score. IN WHICH CASE, the Q2 above stands (i.e., the baselines numbers on 16 and 21 should match).

IRRESPECTIVE, the good news is that AVXL is standing by the key numbers of relevance:

1. ADAS-Cog: Delta benefit of 1.85 with p - 0.033
2. CDR-SB: Delta benefit of 0.41 with p = 0.04

I'm not sure how they are getting the p values even if I agree with everything else they say!

[VuBru]

Unless you impute, how do you propose to do ITT analyses on changes from baseline to 48 week follow-up if you do not have follow-up data? Missing follow-up is why they were not included in the analysis.